(0.23%) 5 143.50 points
(0.19%) 38 515 points
(0.33%) 17 904 points
(-0.64%) $83.31
(1.82%) $1.958
(0.07%) $2 348.90
(0.19%) $27.59
(0.72%) $928.75
(-0.15%) $0.933
(-0.20%) $11.00
(-0.26%) $0.798
(1.15%) $92.93
2 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 10.01%
@ $45.57
发出时间: 27 Apr 2024 @ 01:28
回报率: -0.09%
上一信号: Apr 25 - 22:28
上一信号:
回报率: 1.58 %
Live Chart Being Loaded With Signals
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer...
Stats | |
---|---|
今日成交量 | 864 318 |
平均成交量 | 1.14M |
市值 | 3.36B |
EPS | $0 ( 2024-02-27 ) |
下一个收益日期 | ( $-1.190 ) 2024-05-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -8.84 |
ATR14 | $2.60 (5.71%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Ashar Bhavesh | Sell | 1 824 | Common Stock |
2024-02-16 | Pichl Daniel | Buy | 15 000 | Common Stock |
2024-02-16 | Pichl Daniel | Sell | 15 000 | Common Stock |
2024-02-16 | Pichl Daniel | Sell | 15 000 | Stock Option (Right to Buy) |
2024-02-02 | Ashar Bhavesh | Sell | 1 089 | Common Stock |
INSIDER POWER |
---|
25.98 |
Last 99 transactions |
Buy: 2 487 277 | Sell: 1 935 911 |
音量 相关性
Springworks Therapeutics 相关性 - 货币/商品
Springworks Therapeutics 财务报表
Annual | 2023 |
营收: | $5.45M |
毛利润: | $5.03M (92.25 %) |
EPS: | $-5.15 |
FY | 2023 |
营收: | $5.45M |
毛利润: | $5.03M (92.25 %) |
EPS: | $-5.15 |
FY | 2022 |
营收: | $6.15M |
毛利润: | $4.25M (69.16 %) |
EPS: | $-5.14 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-4.02 |
Financial Reports:
No articles found.
Springworks Therapeutics
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。